Miriana d'Alessandro, Sara Gangi, Irene Paggi, Piera Soccio, Laura Bergantini, Tommaso Pianigiani, Giusy Montuori, Giorgia Moriondo, Giulio Natalello, Sofia Marrucci, Alfonso Brogna, Giulia Scioscia, Donato Lacedonia, Paolo Cameli, Elena Bargagli
{"title":"纤维化间质性肺病 KL-6 周围和肺泡浓度的 CLEIA 与 FEIA 诊断性能对比：一项多中心研究。","authors":"Miriana d'Alessandro, Sara Gangi, Irene Paggi, Piera Soccio, Laura Bergantini, Tommaso Pianigiani, Giusy Montuori, Giorgia Moriondo, Giulio Natalello, Sofia Marrucci, Alfonso Brogna, Giulia Scioscia, Donato Lacedonia, Paolo Cameli, Elena Bargagli","doi":"10.1002/jcla.25108","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Interstitial lung diseases (ILD) is a group of lung disorders characterized by interstitial lung thickening due to inflammatory and fibrotic processes. Krebs von den Lungen-6 (KL-6) is a molecule secreted by damaged type II alveolar pneumocytes in the alveolar space. The goal of the present study was to compare two detection methods of KL-6 in both bronchoalveolar lavage (BAL) and serum from ILD patients at the moment of diagnosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients with suspicious of ILD and followed at two Italian referral centres for rare lung diseases were included in the study. BAL fluid and serum were collected and analysed by chemiluminescent enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) methods provided by Tosoh Biosciences.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 158 (mean age ± standard deviation, 61.5 ± 13.7, 65 females) patients were enrolled. A total of, 36 had diagnosis of idiopathic pulmonary fibrosis (IPF), 74 sarcoidosis, 15 connective tissue disease-ILD (CTD-ILD) and 33 other ILD. Diagnostic agreement between two methods was demonstrated for both BAL (<i>r</i> = 0.707, <i>p</i> < 0.0001) and serum (<i>r</i> = 0.816, <i>p</i> < 0.0001). BAL KL-6 values were lower than serum (<i>p</i> < 0.0001). IPF patients had higher serum KL-6 concentration than other ILDs (<i>p</i> = 0.0294), while BAL KL-6 values were lower in IPF than in non-IPF (<i>p</i> = 0.0023).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study explored KL-6 concentrations through the CLEIA method in serum and BAL of patients with various ILDs, showing significant differences of biomarkers concentrations between IPF and other non-IPF ILDs. Our findings are promising as they provided further knowledge concerning KL-6 expression across different ILDs and may suggest its utility in differential diagnosis.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"38 19-20","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.25108","citationCount":"0","resultStr":"{\"title\":\"Diagnostic Performance of CLEIA Versus FEIA for KL-6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study\",\"authors\":\"Miriana d'Alessandro, Sara Gangi, Irene Paggi, Piera Soccio, Laura Bergantini, Tommaso Pianigiani, Giusy Montuori, Giorgia Moriondo, Giulio Natalello, Sofia Marrucci, Alfonso Brogna, Giulia Scioscia, Donato Lacedonia, Paolo Cameli, Elena Bargagli\",\"doi\":\"10.1002/jcla.25108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Interstitial lung diseases (ILD) is a group of lung disorders characterized by interstitial lung thickening due to inflammatory and fibrotic processes. Krebs von den Lungen-6 (KL-6) is a molecule secreted by damaged type II alveolar pneumocytes in the alveolar space. The goal of the present study was to compare two detection methods of KL-6 in both bronchoalveolar lavage (BAL) and serum from ILD patients at the moment of diagnosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Patients with suspicious of ILD and followed at two Italian referral centres for rare lung diseases were included in the study. BAL fluid and serum were collected and analysed by chemiluminescent enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) methods provided by Tosoh Biosciences.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 158 (mean age ± standard deviation, 61.5 ± 13.7, 65 females) patients were enrolled. A total of, 36 had diagnosis of idiopathic pulmonary fibrosis (IPF), 74 sarcoidosis, 15 connective tissue disease-ILD (CTD-ILD) and 33 other ILD. Diagnostic agreement between two methods was demonstrated for both BAL (<i>r</i> = 0.707, <i>p</i> < 0.0001) and serum (<i>r</i> = 0.816, <i>p</i> < 0.0001). BAL KL-6 values were lower than serum (<i>p</i> < 0.0001). IPF patients had higher serum KL-6 concentration than other ILDs (<i>p</i> = 0.0294), while BAL KL-6 values were lower in IPF than in non-IPF (<i>p</i> = 0.0023).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study explored KL-6 concentrations through the CLEIA method in serum and BAL of patients with various ILDs, showing significant differences of biomarkers concentrations between IPF and other non-IPF ILDs. Our findings are promising as they provided further knowledge concerning KL-6 expression across different ILDs and may suggest its utility in differential diagnosis.</p>\\n </section>\\n </div>\",\"PeriodicalId\":15509,\"journal\":{\"name\":\"Journal of Clinical Laboratory Analysis\",\"volume\":\"38 19-20\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.25108\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Laboratory Analysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jcla.25108\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.25108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：间质性肺疾病（ILD）是一组以炎症和纤维化过程导致的肺间质增厚为特征的肺部疾病。Krebs von den Lungen-6 (KL-6) 是肺泡间隙中受损的 II 型肺泡气细胞分泌的一种分子。本研究的目的是比较两种检测方法，即在确诊 ILD 患者的支气管肺泡灌洗液（BAL）和血清中检测 KL-6：研究对象包括在意大利两家罕见肺病转诊中心就诊的疑似 ILD 患者。采集BAL液和血清，用东曹（Tosoh）生物科学公司提供的化学发光酶免疫分析法（CLEIA）和荧光酶免疫分析法（FEIA）进行分析：共招募了 158 名患者（平均年龄 ± 标准差，61.5 ± 13.7，女性 65 名）。其中，36 人被诊断为特发性肺纤维化（IPF），74 人被诊断为肉样瘤病，15 人被诊断为结缔组织病-ILD（CTD-ILD），33 人被诊断为其他 ILD。两种方法对 BAL 的诊断结果一致（r = 0.707，p 结论）：本研究通过 CLEIA 方法检测了各种 ILD 患者血清和 BAL 中的 KL-6 浓度，结果显示 IPF 和其他非 IPF ILD 之间的生物标志物浓度存在显著差异。我们的研究结果很有希望，因为它们提供了有关不同 ILD 中 KL-6 表达的进一步知识，并可能提示其在鉴别诊断中的作用。
Diagnostic Performance of CLEIA Versus FEIA for KL-6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study
Background
Interstitial lung diseases (ILD) is a group of lung disorders characterized by interstitial lung thickening due to inflammatory and fibrotic processes. Krebs von den Lungen-6 (KL-6) is a molecule secreted by damaged type II alveolar pneumocytes in the alveolar space. The goal of the present study was to compare two detection methods of KL-6 in both bronchoalveolar lavage (BAL) and serum from ILD patients at the moment of diagnosis.
Methods
Patients with suspicious of ILD and followed at two Italian referral centres for rare lung diseases were included in the study. BAL fluid and serum were collected and analysed by chemiluminescent enzyme immunoassay (CLEIA) and fluorescent enzyme immunoassay (FEIA) methods provided by Tosoh Biosciences.
Results
A total of 158 (mean age ± standard deviation, 61.5 ± 13.7, 65 females) patients were enrolled. A total of, 36 had diagnosis of idiopathic pulmonary fibrosis (IPF), 74 sarcoidosis, 15 connective tissue disease-ILD (CTD-ILD) and 33 other ILD. Diagnostic agreement between two methods was demonstrated for both BAL (r = 0.707, p < 0.0001) and serum (r = 0.816, p < 0.0001). BAL KL-6 values were lower than serum (p < 0.0001). IPF patients had higher serum KL-6 concentration than other ILDs (p = 0.0294), while BAL KL-6 values were lower in IPF than in non-IPF (p = 0.0023).
Conclusion
This study explored KL-6 concentrations through the CLEIA method in serum and BAL of patients with various ILDs, showing significant differences of biomarkers concentrations between IPF and other non-IPF ILDs. Our findings are promising as they provided further knowledge concerning KL-6 expression across different ILDs and may suggest its utility in differential diagnosis.
期刊介绍：
Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
